Interventions to address deaths from childhood pneumonia and diarrhoea equitably: What works and at what cost?

Zulfiqar A. Bhutta, Jai K. Das, Neff Walker, Arjumand Rizvi, Harry Campbell, Igor Rudan, Robert E Black

Research output: Contribution to journalArticle

Abstract

Global mortality in children younger than 5 years has fallen substantially in the past two decades from more than 12 million in 1990, to 6•9 million in 2011, but progress is inconsistent between countries. Pneumonia and diarrhoea are the two leading causes of death in this age group and have overlapping risk factors. Several interventions can eff ectively address these problems, but are not available to those in need. We systematically reviewed evidence showing the eff ectiveness of various potential preventive and therapeutic interventions against childhood diarrhoea and pneumonia, and relevant delivery strategies. We used the Lives Saved Tool model to assess the eff ect on mortality when these interventions are applied. We estimate that if implemented at present annual rates of increase in each of the 75 Countdown countries, these interventions and packages of care could save 54% of diarrhoea and 51% of pneumonia deaths by 2025 at a cost of US$3•8 billion. However, if coverage of these key evidence-based interventions were scaled up to at least 80%, and that for immunisations to at least 90%, 95% of diarrhoea and 67% of pneumonia deaths in children younger than 5 years could be eliminated by 2025 at a cost of $6•715 billion. New delivery platforms could promote equitable access and community platforms are important catalysts in this respect. Furthermore, several of these interventions could reduce morbidity and overall burden of disease, with possible benefi ts for developmental outcomes.

Original languageEnglish (US)
Pages (from-to)1417-1429
Number of pages13
JournalThe Lancet
Volume381
Issue number9875
DOIs
StatePublished - Apr 2013

Fingerprint

Diarrhea
Pneumonia
Costs and Cost Analysis
Child Mortality
Cause of Death
Immunization
Age Groups
Morbidity
Mortality
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Interventions to address deaths from childhood pneumonia and diarrhoea equitably : What works and at what cost? / Bhutta, Zulfiqar A.; Das, Jai K.; Walker, Neff; Rizvi, Arjumand; Campbell, Harry; Rudan, Igor; Black, Robert E.

In: The Lancet, Vol. 381, No. 9875, 04.2013, p. 1417-1429.

Research output: Contribution to journalArticle

Bhutta, Zulfiqar A. ; Das, Jai K. ; Walker, Neff ; Rizvi, Arjumand ; Campbell, Harry ; Rudan, Igor ; Black, Robert E. / Interventions to address deaths from childhood pneumonia and diarrhoea equitably : What works and at what cost?. In: The Lancet. 2013 ; Vol. 381, No. 9875. pp. 1417-1429.
@article{0ec06caf8df74b86969a2214e3c79cdb,
title = "Interventions to address deaths from childhood pneumonia and diarrhoea equitably: What works and at what cost?",
abstract = "Global mortality in children younger than 5 years has fallen substantially in the past two decades from more than 12 million in 1990, to 6•9 million in 2011, but progress is inconsistent between countries. Pneumonia and diarrhoea are the two leading causes of death in this age group and have overlapping risk factors. Several interventions can eff ectively address these problems, but are not available to those in need. We systematically reviewed evidence showing the eff ectiveness of various potential preventive and therapeutic interventions against childhood diarrhoea and pneumonia, and relevant delivery strategies. We used the Lives Saved Tool model to assess the eff ect on mortality when these interventions are applied. We estimate that if implemented at present annual rates of increase in each of the 75 Countdown countries, these interventions and packages of care could save 54{\%} of diarrhoea and 51{\%} of pneumonia deaths by 2025 at a cost of US$3•8 billion. However, if coverage of these key evidence-based interventions were scaled up to at least 80{\%}, and that for immunisations to at least 90{\%}, 95{\%} of diarrhoea and 67{\%} of pneumonia deaths in children younger than 5 years could be eliminated by 2025 at a cost of $6•715 billion. New delivery platforms could promote equitable access and community platforms are important catalysts in this respect. Furthermore, several of these interventions could reduce morbidity and overall burden of disease, with possible benefi ts for developmental outcomes.",
author = "Bhutta, {Zulfiqar A.} and Das, {Jai K.} and Neff Walker and Arjumand Rizvi and Harry Campbell and Igor Rudan and Black, {Robert E}",
year = "2013",
month = "4",
doi = "10.1016/S0140-6736(13)60648-0",
language = "English (US)",
volume = "381",
pages = "1417--1429",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9875",

}

TY - JOUR

T1 - Interventions to address deaths from childhood pneumonia and diarrhoea equitably

T2 - What works and at what cost?

AU - Bhutta, Zulfiqar A.

AU - Das, Jai K.

AU - Walker, Neff

AU - Rizvi, Arjumand

AU - Campbell, Harry

AU - Rudan, Igor

AU - Black, Robert E

PY - 2013/4

Y1 - 2013/4

N2 - Global mortality in children younger than 5 years has fallen substantially in the past two decades from more than 12 million in 1990, to 6•9 million in 2011, but progress is inconsistent between countries. Pneumonia and diarrhoea are the two leading causes of death in this age group and have overlapping risk factors. Several interventions can eff ectively address these problems, but are not available to those in need. We systematically reviewed evidence showing the eff ectiveness of various potential preventive and therapeutic interventions against childhood diarrhoea and pneumonia, and relevant delivery strategies. We used the Lives Saved Tool model to assess the eff ect on mortality when these interventions are applied. We estimate that if implemented at present annual rates of increase in each of the 75 Countdown countries, these interventions and packages of care could save 54% of diarrhoea and 51% of pneumonia deaths by 2025 at a cost of US$3•8 billion. However, if coverage of these key evidence-based interventions were scaled up to at least 80%, and that for immunisations to at least 90%, 95% of diarrhoea and 67% of pneumonia deaths in children younger than 5 years could be eliminated by 2025 at a cost of $6•715 billion. New delivery platforms could promote equitable access and community platforms are important catalysts in this respect. Furthermore, several of these interventions could reduce morbidity and overall burden of disease, with possible benefi ts for developmental outcomes.

AB - Global mortality in children younger than 5 years has fallen substantially in the past two decades from more than 12 million in 1990, to 6•9 million in 2011, but progress is inconsistent between countries. Pneumonia and diarrhoea are the two leading causes of death in this age group and have overlapping risk factors. Several interventions can eff ectively address these problems, but are not available to those in need. We systematically reviewed evidence showing the eff ectiveness of various potential preventive and therapeutic interventions against childhood diarrhoea and pneumonia, and relevant delivery strategies. We used the Lives Saved Tool model to assess the eff ect on mortality when these interventions are applied. We estimate that if implemented at present annual rates of increase in each of the 75 Countdown countries, these interventions and packages of care could save 54% of diarrhoea and 51% of pneumonia deaths by 2025 at a cost of US$3•8 billion. However, if coverage of these key evidence-based interventions were scaled up to at least 80%, and that for immunisations to at least 90%, 95% of diarrhoea and 67% of pneumonia deaths in children younger than 5 years could be eliminated by 2025 at a cost of $6•715 billion. New delivery platforms could promote equitable access and community platforms are important catalysts in this respect. Furthermore, several of these interventions could reduce morbidity and overall burden of disease, with possible benefi ts for developmental outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84876287846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876287846&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(13)60648-0

DO - 10.1016/S0140-6736(13)60648-0

M3 - Article

C2 - 23582723

AN - SCOPUS:84876287846

VL - 381

SP - 1417

EP - 1429

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9875

ER -